Eptacog alfa (activated)
NovoSeven (eptacog alfa (activated)) is a protein pharmaceutical. Eptacog alfa (activated) was first approved as NovoSeven on 1996-02-23. It has been approved in Europe to treat factor VII deficiency, hemophilia a, hemophilia b, and thrombasthenia.
| Trade Name | NovoSeven |
|---|---|
| Common Name | Eptacog alfa (activated) |
| Indication | factor vii deficiency, hemophilia a, hemophilia b, thrombasthenia |
| Drug Class |
